Why is "Sodium oxybate" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-13 09:30:21
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Sodium oxybate, sold under the brand name Xyrem among others, is a medication used to treat symptoms of narcolepsy: sudden muscle weakness and excessive daytime sleepiness. It is used sometimes in France and Italy as an anesthetic given intravenously. It is also approved and used in Italy and in Austria to treat alcohol dependence and alcohol withdrawal syndrome.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy | Hypertension - American Heart Association Journals
-
Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment - NeurologyLive
-
Amneal Receives FDA Approval for Sodium Oxybate Oral Solution - Sleep Review
-
Amneal secures FDA approval for sodium oxybate solution - Pharmaceutical Technology
-
Green spectrofluorimetric method for quantification of sodium oxybate in pharmaceutical and plasma samples - Nature
-
Low-Sodium Oxybate Demonstrates Meaningful Blood Pressure Reductions in Patients With Narcolepsy - Pharmacy Times
-
Sodium Oxybate Does Not Worsen AHI in Narcolepsy - Docwire News
-
Tris Pharma Announces FDA Acceptance of NDA for Once-Nightly, Low-Sodium Oxybate Product for Narcolepsy and Idiopathic Hypersomnia - Business Wire
-
Efficacy and Safety of Sodium Oxybate in Adults With Idiopathic Hypersomnia - Neurology® Journals
-
FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia - NeurologyLive
-
FDA Accepts NDA for TRN-257 for Treatment of Narcolepsy and Idiopathic Hypersomnia - Psychiatric Times
-
Alkermes builds out sleep portfolio with $2.1B Avadel takeout - FirstWord Pharma
-
EMA Reviews Alcohol Dependency Drug After French Concerns - Medscape
-
Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy | Hypertension - American Heart Association Journals
-
Alkermes Completes Acquisition of Avadel Pharmaceuticals, Adding LUMRYZ to Portfolio - Sleep Review
-
Impact of Switching from High- to Low-Sodium Oxybate on Ambulatory Blood Pressure in Patients with Narcolepsy - NeurologyLive
-
Low-Sodium Oxybate Improves Daytime Sleepiness and Sleep Architecture in Phase 4 Narcolepsy Trial - NeurologyLive
-
REFRESH Study to Test Real-World Clinical Effectiveness of Once-Nightly Sodium Oxybate - NeurologyLive
-
Post Hoc Analyses Shed Light on Safety and Efficacy of Once-Nightly Sodium Oxybate in Narcolepsy Care - NeurologyLive
-
Jazz Pharmaceuticals Reports Record 2025 Revenue, Driven by Xywav Growth - Sleep Review
-
Low-Sodium Oxybate Lowers Blood Pressure in Narcolepsy - MedPage Today
-
Real-World Data Show Similar Comorbidity Rates With and Without Sodium Oxybate Treatment - NeurologyLive
-
Post-Hoc Analysis Gives Safety Insights on Switch From Twice-Nightly Oxybate to Once-Nightly Treatment - NeurologyLive
-
EU reviews risk of abuse in some treatments for alcohol dependency - Reuters
-
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses - PR Newswire
-
AAN 2025: Low-Sodium Oxybate Improves Sleep Quality, Daily Functioning in Narcolepsy, Idiopathic Hypersomnia - Pharmacy Times
-
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 - PR Newswire
-
Understanding the Approval of Once-Nightly Sodium Oxybate for Pediatric Narcolepsy: Anne Marie Morse, DO, FAASM - NeurologyLive
-
Low-Sodium Oxybate: An Equally Effective but Safer Alternative to High-Sodium Oxybate for Narcolespy - AJMC
-
FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy - NeurologyLive
-
Sodium Oxybate Effective in Idiopathic Hypersomnia, Narcolepsy - AJMC
-
Post Hoc Analysis Shows Once-Nightly Sodium Oxybate Does Not Worsen Apnea-Hypopnea Index in Narcolepsy - NeurologyLive
-
Sodium Oxybate and Antidepressants for Treatment of Cataplexy - NeurologyLive
-
Adverse Events of Low-Sodium Oxybate in Idiopathic Hypersomnia Begin Early in Treatment Course - NeurologyLive
-
Building a Greater Knowledge Profile of Sodium Oxybate Treatment for Narcolepsy: Phil Jochelson, MD - NeurologyLive
-
FDA Approves Once-Nightly Formulation of Sodium Oxybate to Treat Narcolepsy - NeurologyLive
-
Nocturnal Sodium Oxybate Treatment Functional Network Changes Associated With Anterior Cingulate GABA - NeurologyLive
-
How Once-Nightly Sodium Oxybate Changes the Treatment Landscape for Narcolepsy - NeurologyLive
-
FDA Approves Sodium Oxybate to Treat Cataplexy or EDS in Pediatric Patients With Narcolepsy - Pharmacy Times
-
Long-Term Safety and Tolerability of Low-Sodium Oxybate Confirmed - NeurologyLive
-
Sodium Oxybate Demonstrates Long-term Safety and Maintained Efficacy in Pediatric Narcolepsy with Cataplexy - NeurologyLive
-
Low-Sodium Oxybate Improves Excessive Sleepiness Long-term - Docwire News
-
Patient Dosing Begins for Phase 3 Study of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia - NeurologyLive
-
Changes in Sleep Architecture, Comorbidities Observed in Long-Term Treatment With Sodium Oxybate - NeurologyLive
-
In Narcolepsy With Cataplexy, a New Form of Sodium Oxybate Promises Better Long-Term Safety - Cleveland Clinic
-
Once-Nightly Sodium Oxybate Effective in Both Narcolepsy Type 1 and 2 - NeurologyLive
-
FAERS Data Analysis Reveals Insights on Safety Profiles of Narcolepsy Treatments - NeurologyLive
-
Part 3: Advances in Sodium Oxybate Provide Options for Various Patient Populations, Says Dr Michael Thorpy - AJMC
-
Human Medicines Highlights - July 2025 - European Commission
-
Dr Michael Thorpy Explains Benefits of Lower Sodium Oxybate in Narcolepsy, Cataplexy - AJMC
-
Overviewing the XYLO Study and Low-Sodium Oxybate’s Impact on Blood Pressure: Phil Jochelson, MD - NeurologyLive
-
Real-World Data Highlights Reasons for Transitioning From Sodium Oxybate to Lower Sodium Oxybate - NeurologyLive
-
FDA approves sodium oxybate to treat cataplexy, EDS in pediatric narcolepsy patients - Contemporary Pediatrics
-
John Harsh, PhD: Exploring Once-Nightly Sodium Oxybate Therapy for Narcolepsy - HCPLive
-
Efficacy of sodium oxybate on REM sleep behavior disorder in a patient with narcolepsy type 1 - Neurology® Journals
-
Sodium Oxybate Product Trends Reflected in Jazz Pharma’s 2024 Sales - Sleep Review
-
Transforming Medicines to Transform Lives - Nature
-
Sodium Oxybate Improves Nocturnal RBD and REM Sleep Without Atonia in Narcolepsy - NeurologyLive
-
FDA Approves Once-at-bedtime Sodium Oxybate with Orphan Drug Exclusivity for Narcolepsy - HCPLive
-
Once-Nightly Sodium Oxybate Shown to Significantly Improve Symptoms of Narcolepsy - AJMC
-
Treatment Effect of Low-Sodium Oxybate in Idiopathic Hypersomnia Based on ESS, IHSS Scores: Richard Bogan, MD, FCCP, FAASM - NeurologyLive
-
Once-Nightly Sodium Oxybate Preferred in Narcolepsy, ABBV-951 Shines in PD, Ocrelizumab Demonstrates Improved Cognitive Function in Progressive MS - NeurologyLive
-
Trial shows alcohol-mimicking medication can give laryngeal dystonia patients back their voice - EurekAlert!
-
Dr Isabelle Arnulf Highlights Efficacy, Safety of Lower-Sodium Oxybate in Idiopathic Hypersomnia - AJMC
-
Lower Sodium Oxybate May Provide Weight Loss for Adults with Idiopathic Hypersomnia - HCPLive
-
Avadel Pharmaceuticals Urges FDA to Make Decision on Extended-Release Formulation of Sodium Oxybate - NeurologyLive
-
Lower Sodium Oxybate for Excessive Sleepiness, Narcolepsy, and Hypersomnia: Nancy Foldvary-Schaefer, DO, MS - NeurologyLive
-
Weight Changes with Lower-Sodium Oxybate in Idiopathic Hypersomnia - Psychiatry Advisor
-
Lumryz Approval Expanded to Include Pediatric Narcolepsy - MPR - Medical Professionals Reference
-
FDA Gives Final Approval to Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults With Narcolepsy - Pharmacy Times
-
Stanford researcher shows once-nightly narcolepsy drug is safe, effective - Stanford Medicine
-
Presentation: Improvement of Narcolepsy Symptoms with Once-Nightly Sodium Oxybate - Psychiatric Times
-
Sodium Oxybate Approved, ANAVEX 2-73 Shows Positive Results, Ubrogepant for Acute Migraine Care, and Stroke Risk with Migraine - NeurologyLive
-
A novel therapeutic agent, sodium oxybate, improves dystonic symptoms via reduced network-wide activity - Nature
-
FDA Approves Expanded Use for Sodium Oxybate in Cataplexy, Excessive Daytime Sleepiness in Pediatric Narcolepsy - NeurologyLive
-
FDA Accepts Sodium Oxybate Application for Children With Narcolepsy - NeurologyLive
-
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients - PR Newswire
-
Avadel to Present New Data on Lumryz for Narcolepsy at SLEEP 2024 - Sleep Review
-
Jazz Pharmaceuticals Reaches $145 Million Settlement Over Alleged Efforts to Block Generic Xyrem - PYMNTS.com
-
FDA Approves Sodium Oxybate ( Xyrem ) for Pediatric Narcolepsy - Medscape
-
Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy - PR Newswire
-
NSS - Dove Medical Press
-
Laryngeal Dystonia Symptoms Improve With Novel Treatment - MedPage Today
-
Xyrem Generic for Narcolepsy Launches in US - Sleep Review
-
Resolution of Sleepwalking Behavior after Initiation of Sodium Oxybate in a Patient with Narcolepsy Type 2 - Cureus
-
NSS - Dove Medical Press
-
A Potential Fix Emerges for Narcolepsy Medication’s Palatability - Sleep Review
-
Lumryz Associated with Weight Loss in Patients with Narcolepsy - Applied Clinical Trials Online
-
Once-Nightly Narcolepsy Drug Preferred by Patients Over Twice-Nightly Dose - MedPage Today
-
Can a Narcolepsy Drug Improve Sleep In PD? - NeurologyLive
-
FDA Approves Once-Nightly Lumryz for Patients With Narcolepsy - Medical Professionals Reference
-
Alcohol-mimicking drug found to ease voice spasm that RFK Jr has - BBC
-
Journal of Sleep Research | ESRS Journal - Wiley Online Library
-
Doctors Are Prescribing GHB for Narcolepsy - respiratory-therapy.com
-
Advances in the Treatment of Narcolepsy With Cataplexy: Role of Selective Histamine Receptor Modulation - Neurology Advisor
-
FDA Grants Final Approval for Treatment of Cataplexy in Adults With Narcolepsy - Psychiatric Times
-
Tris Pharma Is Working on a Low Sodium, Once-Nightly Oxybate Formulation for Narcolepsy - Sleep Review
-
FDA Approves Oral Suspension Tx for Narcolepsy – Lumryz - Anton Health
-
FDA Approves JZP-258 for Cataplexy and Daytime Sleepiness - NeurologyLive
-
New Treatment for Cataplexy - Sleep Review
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.